BeOne Medicines Ltd. (BEIGF) intrinsic value & 10-year financials
BeOne Medicines Ltd. (BEIGF) has a Graham intrinsic value of $6.31 per share. Over the last 10 fiscal years revenue grew 157.6% a year to $5.3B, with an average return on invested capital of -64.4%.
- Graham intrinsic value
- $6.31
- Revenue (FY2025)
- $5.3B
- Revenue growth (10-yr CAGR)
- 157.6%
- ROIC (10-yr avg)
- -64.4%
- Free cash flow (FY2025)
- $941.7M
BEIGF 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $5.3B | $286.9M | $0.19 | $941.7M | 8.4% | 23.2% |
| FY2024 | $3.8B | -$644.8M | -$0.47 | -$633.3M | -14.9% | -37.4% |
| FY2023 | $2.5B | -$881.7M | -$0.65 | -$1.7B | -49.1% | -102.3% |
| FY2022 | $1.4B | -$2.0B | -$1.49 | -$1.8B | -126.4% | -98.7% |
| FY2021 | $1.2B | -$1.4B | -$1.17 | -$1.6B | -122.3% | -50.7% |
| FY2020 | $308.9M | -$1.6B | -$1.47 | -$1.4B | -536.7% | -94.0% |
| FY2019 | $428.2M | -$948.6M | -$1.22 | -$839.9M | -224.2% | -125.5% |
| FY2018 | $198.2M | -$673.8M | — | -$618.0M | -356.1% | -90.5% |
| FY2017 | $238.4M | -$93.1M | — | -$33.6M | -41.3% | -26.9% |
| FY2016 | $1.1M | -$119.2M | — | -$113.0M | -10940.2% | -41.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
BeOne Medicines Ltd. is a consistent compounder, expanding top-line revenue at 157.6% annually over the past decade.
BeOne Medicines Ltd. has historically struggled to out-earn its cost of capital, averaging just -64.4% ROIC.
BeOne Medicines Ltd. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, BeOne Medicines Ltd. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $6.31 per share.